Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Regulus Therapeutics Inc. (RGLS)
Sector: Healthcare; Industry: Biotechnology

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease.

RGLS Symbol Info by TradingView

Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-02-16 Hagan Joseph P President and CEO Sell 4,144 $1.72 $7,128 No
2021-02-16 Aker Christopher Ray Sr. VP & General Counsel Sell 828 $1.72 $1,424 No
2021-02-16 Hagan Joseph P President and CEO Sell 4,144 $1.72 $7,128 No
2020-12-04 Walker Paul Edward 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Sonsini Peter W. 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 SANDELL SCOTT D 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 MAKOWER JOSHUA 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Makhzoumi Mohamad 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Florence Anthony A. Jr. 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Chang Carmen 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Behbahani Ali 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 BASKETT FOREST 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Growth Equity Opportunities V, LLC 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-11-16 Aker Christopher Ray Sr. VP & General Counsel Sell 876 $0.52 $456 No
2020-11-16 Hagan Joseph P President and CEO Sell 6,094 $0.52 $3,176 No
2020-08-14 Hagan Joseph P President and CEO Sell 4,245 $0.60 $2,568 No
2020-08-14 Aker Christopher Ray Sr. VP & General Counsel Sell 872 $0.60 $528 No
2020-05-15 Hagan Joseph P President and CEO Sell 4,426 $0.63 $2,774 No
2020-05-15 Aker Christopher Ray Sr. VP & General Counsel Sell 909 $0.63 $570 No
2020-02-18 Hagan Joseph P President and CEO Sell 4,324 $0.83 $3,591 No
2020-02-18 Aker Christopher Ray Sr. VP & General Counsel Sell 888 $0.83 $737 No
2020-01-02 Hagan Joseph P President and CEO Sell 8,345 $0.97 $8,067 No
2020-01-02 Aker Christopher Ray Sr. VP & General Counsel Sell 2,239 $0.97 $2,164 No
2019-11-14 Aker Christopher Ray Sr. VP & General Counsel Sell 833 $0.64 $533 No
2019-11-14 Hagan Joseph P President and CEO Sell 5,838 $0.64 $3,736 No
2019-10-01 Aker Christopher Ray Sr. VP & General Counsel Sell 2,346 $0.68 $1,602 No
2019-10-01 Hagan Joseph P President and CEO Sell 8,743 $0.68 $5,969 No
2019-08-15 Hagan Joseph P President and CEO Sell 4,375 $0.55 $2,409 No
2019-08-15 Aker Christopher Ray Sr. VP & General Counsel Sell 899 $0.55 $495 No
2019-07-01 Hagan Joseph P President and CEO Sell 5,783 $1.31 $7,584 No

Insider Smart

CARNIVAL CORP (CCL) - Cruislines $CCL $NCLH $RCL took a huge beat due to the pandemic, concerns of bankruptcy were raised. Among the three dominating companies in the industry, $CCL is the first one bought by insiders, such a bold move would definitely boost investor confidence.